JBC Avanti Polar Lipids

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ren, B.
Right arrow Articles by Jump, D. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ren, B.
Right arrow Articles by Jump, D. B.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Volume 272, Number 43, Issue of October 24, 1997 pp. 26827-26832
©1997 by The American Society for Biochemistry and Molecular Biology, Inc.

Polyunsaturated Fatty Acid Suppression of Hepatic Fatty Acid Synthase and S14 Gene Expression Does Not Require Peroxisome Proliferator-activated Receptor alpha *

(Received for publication, March 21, 1996, and in revised form, June 20, 1997)

Bing Ren Dagger , Annette P. Thelen Dagger , Jeffrey M. Peters §, Frank J. Gonzalez § and Donald B. Jump Dagger

From the Dagger  Departments of Biochemistry and Physiology, Michigan State University, East Lansing, Michigan 48824 and § Laboratory of Metabolism NCI, National Institutes of Health, Bethesda, Maryland 20892

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

Dietary polyunsaturated fatty acids (PUFA) induce hepatic peroxisomal and microsomal fatty acid oxidation and suppress lipogenic gene expression. The peroxisome proliferator-activated receptor alpha  (PPARalpha ) has been implicated as a mediator of fatty acid effects on gene transcription. This report uses the PPARalpha -deficient mouse to examine the role of PPARalpha in the PUFA regulation of mRNAs encoding hepatic lipogenic (fatty acid synthase (FAS) and the S14 protein (S14)), microsomal (cytochrome P450 4A2 (CYP4A2)), and peroxisomal (acyl-CoA oxidase (AOX)) enzymes. PUFA ingestion induced mRNAAOX (2.3-fold) and mRNACYP4A2 (8-fold) and suppressed mRNAFAS and mRNAS14 by >= 80% in wild type mice. In PPARalpha -deficient mice, PUFA did not induce mRNAAOX or mRNACYP4A2, indicating a requirement for PPARalpha in the PUFA-mediated induction of these enzymes. However, PUFA still suppressed mRNAFAS and mRNAS14 in the PPARalpha -deficient mice. Studies in rats provided additional support for the differential regulation of lipogenic and peroxisomal enzymes by PUFA. These studies provide evidence for two distinct pathways for PUFA control of hepatic lipid metabolism. One requires PPARalpha and is involved in regulating peroxisomal and microsomal enzymes. The other pathway does not require PPARalpha and is involved in the PUFA-mediated suppression of lipogenic gene expression.


INTRODUCTION

Dietary polyunsaturated fatty acids (PUFAs),1 in particular highly unsaturated n-3 fatty acids, suppress hepatic lipogenesis and triglyceride synthesis/secretion while inducing peroxisomal and microsomal fatty acid oxidation (1-12). These effects on lipid metabolism are due to changes in gene expression leading to induction or suppression of mRNAs encoding key metabolic enzymes (4, 13-19). PUFA administration in vivo or to cultured rat hepatocytes rapidly inhibits the transcription of genes encoding fatty acid synthase, stearoyl-CoA desaturase, the S14 protein, and L-type pyruvate kinase (15-19). While the molecular mediators for PUFA regulation of these genes have not been defined, studies on the regulation of peroxisomal enzymes suggest that fatty acids activate a nuclear receptor to control gene transcription (20-24).

Peroxisome proliferators encompass a wide variety of compounds including hypolipidemic drugs (WY14,643, gemfibrozil, and clofibrate), plasticizers (di-(2-ethyhexyl)phthalate), steroids (dehyrdoepiandrosterone and dehyrdoepiandrosterone-sulfate), and dietary fatty acids (25-27). Collectively, peroxisome proliferator-induced changes in gene expression are mediated by activating a nuclear receptor, the peroxisome proliferator-activated receptor (PPAR). PPARs are members of the steroid/thyroid superfamily of nuclear receptors (20-28). Activation of PPAR-mediated transcription is achieved through PPAR-RXR heterodimers which bind DNA motifs called peroxisome proliferator response elements (PPRE) located in promoters of target genes (20-33). PPARs also have inhibitory effects on gene transcription. For example, apolipoprotein CIII and transferrin gene expression is inhibited by PPAR-RXR competition for an HNF-4 binding site within the promoters of these genes (34, 35). PPARalpha has also been shown to interfere with thyroid hormone action by sequestering RXRalpha , a factor required for thyroid hormone receptor binding to DNA (36-38).

The fact that PPARs are activated by fatty acids in conjunction with the known effects of PUFA on peroxisomal and microsomal fatty acid oxidation suggest that PUFA regulation of these pathways might utilize a common transcriptional mediator, i.e. PPAR. While several PPAR subtypes (alpha , beta  (also known as delta , Nuc1, FAAR), gamma 1, and gamma 2) have been identified in rodents, PPARalpha is the predominant form in rodent liver (22-24, 28, 31, 39). Recent gene targeting studies clearly demonstrate that PPARalpha is required for the pleiotropic response to peroxisome proliferators including an increase in hepatic mRNAs encoding peroxisomal and microsomal enzymes (40).

This report examines the role of PPARalpha in PUFA-regulation of mRNAs encoding hepatic lipogenic, microsomal and peroxisomal enzymes. In this work, we assessed PUFA regulation of the S14 gene and fatty acid synthase, models for lipogenic gene expression, and acyl-CoA oxidase (AOX) and cytochrome P450A2 (CYP4A2), enzymes involved in peroxisomal and microsomal fatty acid oxidation, respectively. The recently developed PPARalpha -null mouse (40) was used to determine whether PPARalpha mediates PUFA regulation of hepatic AOX, CYP4A2, S14, and FAS gene expression. This work shows that while PPARalpha is required for the PUFA-mediated induction of both AOX and CYP4A2 gene expression, it is not required for the PUFA-mediated inhibition of either S14 or FAS gene expression. These and other studies indicate that PUFA regulation of hepatic gene transcription involves at least two distinct pathways, a PPARalpha -dependent and a PPARalpha -independent pathway.


MATERIALS AND METHODS

Animals and Diets

Male Sprague-Dawley rats (125-150 g) were obtained from Charles River Breeding Laboratories (Kalamazoo, MI). Male C57BL/6N × Sv/129 mice (25-35 g), F6 homozygote wild-type (+/+) or knockout (-/-) were used for one of the feeding studies (40). Rats and mice were maintained on Teklad chow diet. In all feeding studies, rats and mice were meal-trained to a high carbohydrate diet as described previously (16, 17). The test diets consisted of a high carbohydrate (58% glucose) diet (ICN, Cleveland, OH) supplemented with either 10% (w/w) of complex fats (triolein, olive oil, fish (menhaden)), fatty acid ethyl esters (eicosapentaenoic acid or docosahexaenoic acid (Southeast Fisheries Science Center, Charleston, SC)), or 0.2% gemfibrozil (Sigma). All diets were supplemented with 0.1% butylated hydroxytoluene (17).

RNA Analysis

Total RNA from rat or mouse livers or from cultured rat primary hepatocytes was isolated using the guanidinium isothiocyanate procedure. The following cDNA probes were used to measure specific mRNAs: S14, pExoPEII6 (16); acyl-CoA oxidase, pTZ18R obtained from T. Osumi, Himeji Institute, Japan (41); fatty acid synthase, pFAS1 obtained from H. S. Sul, University of California-Berkeley (42), and beta -actin, pRBA-1, obtained from L. Kedes, Stanford University, Palo Alto, CA.

The cDNA for CYP4A2 was cloned by differential display screening (43) of rat liver RNA. First strand cDNA was prepared (Delta RNA Fingerprinting Kit, K1801-1, CLONTECH) from rat liver RNA of rats fed olive oil and fish oil for 5 days. PCR was performed using a Perkin-Elmer DNA thermal cycler 9600 as follows: one cycle of 94 °C, 10 s; 40 °C, 5 min; 68 °C, 5 min; two cycles of 94 °C, 5 s; 40 °C, 5 min, 68 °C, 5 min; 25 cycles of 94 °C 5 s; 60 °C, 1 min; and 68 °C, 2 min for 30 cycles of 95 °C/min; 60 °C/min; 72 °C/min. 35S-Labeled PCR products were separated by denaturing polyacrylamide gel electrophoresis and visualized by autoradiography. A band present in the fish oil derived cDNA and diminished in the olive oil derived cDNA was excised from the gel, reamplified by PCR, and cloned into pGEM-T (Promega). The insert was sequenced by dideoxynucleotide sequencing (44). Computer assisted analysis (GCG, University of Wisconsin) of the cloned sequence with the GenBankTM data base indicated that the cloned sequence was identical to a region of the rat cytochrome P450 4A2 sequence (accession no. 57719) at nucleotides 12624-12728 for the rat gene. This sequence was in the noncoding 3'-untranslated region. To obtain the sequence unique to CYP4A2 and containing the translated sequence, two PCR primers (5'-primer, 5'-atatatgaattc7370CACATGGGACCACCTGG; 3'-primer, 5'-atatatatcgat12650GCTGGGAAGGTG TCTGGAGT (underlined sequence represents EcoRI and ClaI cloning sites, respectively; the superscripted numbers represent the position of the nucleotide in the rat CYP4A2 gene)) were used to generate a cDNA from liver RNA of fish oil-fed rats by reverse transcriptase-PCR. The identity of the clone (pCYP4A2-2) was verified by DNA sequencing and used to measure CYP4A2 mRNA.

mRNA levels were measured by dot and Northern blot analyses (17) and the level of hybridization was quantified using a Molecular Dynamics PhosphorImager (Sunnyvale, CA) or by videodensitometry using an Agfa-2 scanner linked to a Macintosh computer with NIH Image software.

Plasmid Construction and Primary Hepatocytes

The construction of the reporter gene with the rat AOX PPRE fused upstream from the thymidine kinase promoter (TKCAT223) was described previously (38).

Primary hepatocytes were obtained from rat liver by the collagenase perfusion method and transfected with specific DNAs in the presence of Lipofectin (16). Hepatocytes were treated with triiodothyronine along with specific fatty acids or peroxisome proliferators (WY14,643 or gemfibrozil dissolved in Me2SO) (16, 38). After 48 h of treatment, hepatocytes were analyzed for protein and CAT activity (38). CAT activity is defined as CAT units = counts/min of 14C-butylated chloramphenicol/h/100 µg of protein.

Statistical Analysis

All data are presented as the mean ± S.E. Statistical comparisons were made by a single-factor factorial analysis of variance using Microsoft Excel version 7.


RESULTS

The Effects of Olive and Fish Oil on Hepatic Gene Expression in Wild-type (+/+) and PPARalpha Null (-/-) Mice

PPARalpha is the predominant PPAR subtype in rodent liver and has a central role in regulating the transcription of genes encoding hepatic peroxisomal and microsomal enzymes (24, 28, 40). To determine whether PPARalpha mediates PUFA regulation of hepatic gene expression wild type (+/+) and PPARalpha null (-/-), mice were fed an olive oil or fish oil diet for 5 days. Northern analyses show that feeding (+/+) mice fish oil for 5 days resulted in a ~2-fold (p < 0.003) and ~9-fold (p < 0.001) increase in hepatic mRNAAOX and mRNACYP4A2, respectively (Fig. 1, A and B). In contrast, fish oil did not significantly induce mRNAAOX and mRNACYP4A2 in the PPARalpha null (-/-) mice. These results indicate that PPARalpha is required for the PUFA-mediated induction of AOX and CYP4A2 mRNAs. While hepatic beta -actin mRNA was elevated in the (-/-) mice when compared with the (+/+) mice, it was not affected by dietary manipulation.


Fig. 1. The effects of olive and fish oil feeding on levels of mRNAAOX, mRNACYP4A2, mRNAS14, and mRNAFAS from both wild-type (+/+) and PPARalpha null (-/-) mice. Eight mice of each genotype were meal-fed with diets supplemented with 10% olive oil for 10 days. Four of each genotype were switched to a diet supplemented with 10% fish oil for 5 days. Total RNA was prepared from mouse livers and measured for mRNAs encoding AOX, CYP4A2, S14, FAS, and beta -actin by Northern analysis. Ethidium bromide staining of the RNA on a typical agarose gel indicates that the RNA was evenly loaded. The results of the hybridization are displayed (A) and quantified (B). A, The AOX, CYP4A2, S14, and FAS and beta -actin blots were exposed to x-ray film for 36, 18, 24, 24, and 18 h, respectively. B, the level of hybridization was quantified by a PhosphorImager and normalized against the level of expression of the corresponding mRNAs in olive oil-fed mouse liver; n = 4. The statistical comparison (analysis of variance, ANOVA) was for olive oil versus fish oil-fed mice. N.S., not significant.

[View Larger Version of this Image (38K GIF file)]


Analysis of mRNAs encoding S14 and FAS shows both mRNAs were suppressed (>= 70%) in both the wild type (+/+) and PPARalpha null (-/-) mice following fish oil feeding. Since PUFA rapidly inhibits the transcription of both the S14 and the FAS gene (16, 17), these observations indicate that PPARalpha is not required for the PUFA-mediated suppression of transcription of these genes.

The Effects of Olive Oil and Fish Oil on Hepatic AOX and S14 Gene Expression

Previous studies have shown that S14 and FAS are regulated by PUFA and peroxisomal proliferators in rat liver or primary hepatocytes (17, 45). The studies described below compare the PUFA and peroxisome proliferator regulation of S14 and AOX in rat liver and primary hepatocytes. These in vivo and in vitro (rat primary hepatocytes) studies were performed to gain additional support for the idea that PUFA regulation of lipogenic gene expression is a result of a different pathway than PUFA regulation of AOX gene expression.

Rats were meal-fed diets supplemented with 10% olive oil, fish oil, eicosapentaenoic acid (20:5), or docosahexaenoic acid (22:6) for 5 days. When compared with chow-fed rats, hepatic mRNAAOX is elevated ~40% in olive oil-fed rats and ~3-fold in fish oil-, 20:5-, and 22:6-fed rats (Fig. 2). mRNACYP4A2 was induced >10-fold under similar conditions.2 While mRNAS14 is induced ~2-fold by the olive oil feeding, fish oil, 20:5, and 22:6 suppressed mRNAS14 by >= 78%. Hepatic mRNAFAS is also suppressed in fish oil-fed rats (17). Feeding mice (Fig. 1) or rats (Fig. 2) fish oil or their highly unsaturated fatty acid constituents (20:5 (n-3) or 22:6 (n-3)) leads to a pronounced induction of mRNAAOX and mRNACYP4A2 while inhibiting expression of mRNAS14 and mRNAFAS.


Fig. 2. A comparison of the effect of olive oil and fish oil on hepatic S14 and AOX gene expression in vivo. Rats were meal-fed with diets supplemented with 10% (w/w) olive oil, menhaden (fish) oil, eicosapentaenoic acid (20:5), or docosahexaenoic acid (22:6) for 5 days. Total hepatic RNA was prepared and examined by dot-blot analysis for the effect of feeding on mRNAAOX and mRNAS14 levels. The results were quantified and normalized against the level of hepatic mRNA expressed in chow-fed rats, i.e. 1 unit. Analysis of variance for both mRNAAOX and mRNAS14 levels for menhaden oil-, 20:5-, and 22:6-fed versus olive oil-fed, p < 0.002. These results are representative of two separate studies; n = 4.

[View Larger Version of this Image (22K GIF file)]


Time Course of Fish Oil and Gemfibrozil Effects on Hepatic S14 and AOX Gene Expression in Vivo

The rapidity of fish oil action on hepatic mRNAAOX and mRNAS14 was examined in rats fed fish oil for 1 to 5 days (Fig. 3A). Rats were meal-fed a high carbohydrate diet supplemented with10% triolein oil for 10 days. Subsequently, half of the rats were maintained on this diet and half were switched to a high carbohydrate diet supplemented with 10% fish oil. Fish oil feeding induced a rapid suppression of mRNAS14; a 60% suppression was observed within 1 day of switching the diet from triolein to fish oil. Similar effects on mRNAs encoding FAS and L-pyruvate kinase have were reported previously (17). In contrast, mRNAAOX remained unaffected after 1 day on the fish oil diet, yet was induced 2- and 3.5-fold after 2 and 5 days, respectively. Such studies indicate that changes in S14 mRNA precede changes in AOX mRNA following initiation of fish oil feeding, but they do not argue against PPARalpha as a common mediator for the PUFA-regulation of AOX and S14.


Fig. 3. Time course of fish oil and gemfibrozil effects on rat hepatic S14 and AOX gene expression. A, rats were meal-fed diets supplemented with 10% (w/w) triolein oil for 10 days. Half of the rats were maintained on triolein oil, while the other half were switched to the fish oil diet. Both triolein- and fish oil-fed rats were killed after 1, 2, and 5 days. Total liver RNA was prepared and examined by dot-blot analysis for mRNAAOX and mRNAS14 levels; n = 4-10 per time point. These results are representative of two separate studies. The results were quantified and normalized against the level of hepatic mRNA expressed in chow-fed rats, i.e. 1 unit. Analysis of variance: a, 1-, 2-, and 5-day fish oil feeding on mRNAS14 versus triolein oil fed mRNAS14, p < 0.001; b, 2- and 5-day fish oil feeding on mRNAAOX versus triolein oil fed mRNAAOX, p < 0.001. B, after meal-training rats to a high carbohydrate fat-free diet, half of the rats were maintained on the high carbohydrate, fat-free diet, while the other half was switched to a diet supplemented with 0.2% (w/w) gemfibrozil for 2, 4, and 8 days. Dot-blot analysis was used to measure the mRNAAOX and mRNAS14 levels. The results were quantified and normalized against the level of hepatic mRNA expressed in chow-fed rats, i.e. 1 unit; n = 3-4 per time point. These results are representative of two separate studies. Analysis of variance: a, 2, 4, and 8 days, gemfibrozil versus control diet fed, mRNAAOX, p < 0.004; b, 4-day gemfibrozil fed versus control diet fed, mRNAS14, p = 0.002.

[View Larger Version of this Image (18K GIF file)]


In an effort to separate the induction of AOX from the suppression of S14, the peroxisome proliferator, gemfibrozil was fed to rats at 0.2% (w/w) for up to 8 days (Fig. 3B). mRNAAOX was induced ~4-fold after 4 days on gemfibrozil, a level comparable to the level of mRNAAOX after 5 days on fish oil. In contrast, gemfibrozil did not significantly suppress mRNAS14 (Fig. 3B) or mRNAFAS (not shown). Only a modest 22% inhibition of mRNAS14 was seen after 4 days of gemfibrozil feeding. These results show that mRNAs encoding both S14 and AOX are affected by PUFA within 2 days of initiating fish oil feeding. However, the absence of a significant inhibition of mRNAS14 following 8 days of gemfibrozil feeding argues against PPARalpha as a common mediator for PUFA regulation of both AOX and S14 gene expression.

Effect of Fatty Acids on AOX and S14 Gene Expression in Primary Hepatocytes

Primary hepatocytes provide a method to assess the direct effects of PUFA on hepatic gene expression (16, 17). To examine the effects of fatty acids on S14 and AOX mRNAs, primary rat hepatocytes were treated with albumin alone or albumin plus various fatty acids (Fig. 4). Treatment of primary hepatocytes with 18:1, 18:2, 18:3 (both n-3 and n-6), and 20:4 did not induce mRNAAOX. Only 20:5 treatment induced mRNAAOX (~2-fold). This finding is consistent with the effects of highly unsaturated fatty acids on AOX gene expression in vivo (Figs. 1 and 2). Oleic acid (18:1) did not affect S14 gene expression when compared with controls. However, 18:2 (n-6) resulted in ~50% decline and 18:3 (both n-3 and n-6), 20:4 (n-6) and 20:5 (n-3) treatment resulted in >80% suppression of hepatocyte mRNAS14 levels. These findings demonstrate that a broader spectrum of fatty acids affect S14 gene expression than AOX gene expression in primary rat hepatocytes.


Fig. 4. A comparison of various fatty acids on S14 and AOX gene expression in primary rat hepatocytes. Primary rat hepatocytes prepared by the collagenase perfusion were plated into 100-mm Primaria tissue culture plates in the presence of 1 µM triiodothyronine, 1 µM insulin, and 50 µM albumin. The cells were maintained in medium containing different fatty acids (250 µM) for 48 h (17). Total RNA was prepared from the hepatocytes and analyzed by dot blot analysis for mRNA coding for AOX and S14. The results were quantified and normalized against the level of AOX or S14 mRNA expressed in hepatocytes receiving no fatty acid treatment (albumin control). Analysis of variance: a, 18:1 (n-9)-, 18:2 (n-6)-, 18:3 (n-3)-, 18:3 (n-6)-, or 20:4 (n-6)-treated mRNAAOX versus albumin-treated mRNAAOX, p >=  0.07; b, 20:5 (n-3)-treated mRNAAOX versus albumin-treated mRNAAOX, p = 0.006; c, 18:1-treated mRNAS14 versus albumin-treated mRNAS14, p = 0.01; d, 18:2 (n-6)-, 18:3 (n-3)-, 18:3 (n-6)-, 20:4 (n-6)-, or 20:5 (n-3)-treated mRNAS14 versus albumin-treated mRNAS14, p <=  0.0004. These results are representative of two separate studies; n = 4.

[View Larger Version of this Image (29K GIF file)]


Fatty Acid Effects on Reporter Gene Activity in Primary Hepatocytes

To determine if fatty acids activate PPARalpha in liver, primary hepatocytes were transfected with a reporter gene containing the AOX PPRE fused to the thymidine kinase promoter, i.e. TKCAT223 (38). Primary hepatocytes were co-transfected with pSG5 (empty vector) or pSG5-mPPARalpha , a PPARalpha expression vector (Fig. 5). In the absence of co-transfected PPARalpha , TKCAT223 CAT activity was expressed at low levels (<150 CAT units) and this activity was marginally affected by fatty acid or peroxisome proliferator (WY14,643, gemfibrozil) treatment. Co-transfection with pSG5-PPARalpha led to at least a 10-fold stimulation of the TKCAT223 activity. Treatment of PPARalpha -transfected hepatocytes with 18:1 and 20:4 had no effect on CAT activity, while 20:5 treatment induced CAT activity by ~2-fold. This pattern of fatty acid regulation of PPARalpha is consistent with the effects of these fatty acids on mRNAAOX (Fig. 4). By comparison, both WY14,643 and gemfibrozil induced CAT activity by 4-fold. These studies show that long chain unsaturated fatty acids such as 18:1, 18:2, 18:3 (n-3 and n-6), and 20:4 do not activate PPARalpha in primary hepatocytes. Only the highly unsaturated fatty acid, 20:5, n-3 activates PPARalpha , albeit to a level less than WY14,643 or gemfibrozil. This pattern of control contrasts with the known effects of fatty acids on mRNAS14 (16, 17) (Fig. 4) and S14CAT activity3 in primary hepatocytes where 18:2 (n-6), 18:3 (n-3 and n-6), 20:4 (n-6), and 20:5 (n-3) inhibit S14 gene expression 50-80%.


Fig. 5. Activation of PPARalpha by fatty acids and peroxisome proliferators. Primary hepatocytes co-transfected with TKCAT223 (1 µg) in the presence of 0.5 µg of pSG5 (open bars) or pSG5-PPARalpha (closed bars). The cells were treated with different fatty acids at the concentration of 250 µM in the presence of 50 µM albumin. A second group of cells were treated with either 100 µM WY14,643 or 100 µM gemfibrozil. Medium was replaced after 24 h, and cells were harvested after 48 h of treatment and assayed for protein levels and CAT activity. Analysis of variance: a, without PPARalpha , 18:1, 20:4, or 20:5 versus albumin, p >=  0.3; b, with PPARalpha , 18:1, or 20:4 versus albumin, p >=  0.1; c, with PPARalpha , 20:5 versus albumin, p = 0.04; d, with or without PPARalpha , p <=  0.007. These results are representative of at least two separate studies; n = 3/study.

[View Larger Version of this Image (23K GIF file)]



DISCUSSION

PPARalpha is the predominant PPAR subtype expressed in rat liver and it plays a central role in the induction of hepatic peroxisomal and microsomal fatty acid oxidation (24, 40). Since several peroxisomal, microsomal and lipogenic enzymes are regulated by PUFA at the pretranslational level, we tested the hypothesis that dietary PUFA regulate hepatic fatty acid oxidation and de novo lipogenesis through a common mediator, i.e. PPARalpha . Interestingly, all studies reporting on fatty acid regulation of PPARalpha have been carried out by over expressing receptors in established cell lines. No studies have directly examined the role PPARalpha may have in fatty acid-regulated hepatic gene transcription. The PPARalpha -null mouse allows such an analysis. Coupling this genetic approach with other studies has allowed us to show for the first time that 1) PPARalpha is required for PUFA-mediated induction of hepatic mRNAAOX and mRNACYP4A2 (Fig. 1); 2) PPARalpha is not required for PUFA-mediated suppression of mRNAS14 or mRNAFAS (Fig. 1); 3) while 18:2 (n-6), 18:3 (n-6 and n-3), 20:4 (n-6) and 20:5 (n-3) suppress mRNAS14 and mRNAFAS, only 20:5 (n-3) induces mRNAAOX in primary hepatocytes (Fig. 4); 4) while gemfibrozil induces hepatic mRNAAOX, it has little or no effect on mRNAS14 or mRNAFAS (Fig. 3). Taken together, these studies indicate that PUFA control of peroxisome/microsomal fatty acid oxidation and de novo lipogenesis in rat liver does not involved PPARalpha as a common mediator. The differential effect of specific fatty acids, i.e. 18:2, 18:3 (n-3 and n-6), 20:4 (n-6), versus gemfibrozil underscores the lack of coordinate regulation of these pathways in rat liver. Such studies indicate that PUFA regulates at least two pathways in liver, one involves PPARalpha and controls expression of genes encoding proteins involved in peroxisomal and microsomal fatty acid oxidation. The other mechanism is PPARalpha -independent and is involved in the PUFA-mediated suppression of lipogenic gene expression.

PUFA suppress hepatic mRNAS14 and mRNAFAS levels by inhibiting gene transcription (15-17). From the data reported above, this inhibitory mechanism does not require PPARalpha . Although the mechanism of PUFA induction of hepatic mRNAAOX and mRNACYP4A2 has not been established, the following studies implicate transcription as the principal mode of PUFA regulation of AOX and CYP4A: 1) peroxisomal proliferators rapidly induce transcription of genes encoding AOX, the bifunctional enzyme, thiolase and CYP4A subtypes 1-3 (26, 40); 2) PPARalpha is required for the induction of these genes (40); 3) PPARalpha binds PPREs as PPAR/RXR heterodimers in the promoters of these genes and stimulates transcription of cis-linked reporter genes (20-33, 38); 4) fatty acids activate PPARalpha and stimulate transcription of cis-linked reporter genes (20-33) (Fig. 5); and 5) PPARalpha is required for the PUFA induction of hepatic mRNAAOX and mRNACYP4A2 (Fig. 1).

Previous efforts to examine the involvement of PPARalpha in PUFA regulation of lipogenic gene expression showed that the cis-regulatory targets for PUFA and PPAR in the S14 promoter (38, 45) did not converge. Analysis of stearoyl-CoA desaturase 1 gene expression indicated that peroxisome proliferators/PPAR induced by PUFA-suppressed transcription (46). Such studies argued against PPAR as a mediator of PUFA effects on lipogenic gene transcription. However, the over expression of receptors does not necessarily reflect physiologically relevant processes. The use of the PPARalpha -null mouse allows us to directly evaluate the role PPARalpha plays in PUFA regulation of hepatic gene expression. In contrast to (+/+) mice, hepatic mRNAAOX and mRNACYP4A2 was not significantly induced in PPARalpha (-/-) mice by the PUFA diet indicating a requirement for PPARalpha in the PUFA-mediated induction of these enzymes. The fact that hepatic mRNAS14 and mRNAFAS was suppressed in both (+/+) and (-/-) mice provides strong evidence against a requirement for PPARalpha for PUFA-mediated suppression of S14 and FAS gene transcription. While these studies confirm our earlier suggestion that PPAR did not mediate PUFA suppression of S14 gene transcription, they provide new information on the requirement for PPARalpha in the PUFA-induction of AOX and CYP4A2 and the lack of involvement of PPARalpha in PUFA-mediated suppression of FAS gene transcription or L-pyruvate kinase gene expression.2 While other PPAR subtypes (PPARgamma and PPARdelta ) (24, 39) are expressed in liver, Northern analyses suggests PPARgamma and delta  are minor subtypes in rodent liver. However, their role in PUFA control of hepatic gene expression cannot be excluded.

An important outcome of these studies is the finding that of all the PUFA tested, only 20:5 (n-3) activates PPARalpha in liver. Several groups have reported on fatty acid activation of PPARs in established cells lines like CV-1 and HeLa (20-24). Recently three groups reported that specific fatty acids, i.e. 18:2 (n-6), 18:3 (n-3 and n-6), and 20:4 (n-6) are ligands for PPARalpha (47-49). These same ligands do not activate PPARalpha or induce mRNAAOX in primary hepatocytes (Figs. 4 and 5). Feeding animals soybean or corn oil, oils containing 18:2 and 18:3 fatty acids, does not induce peroxisomal enzymes (4). This apparent conflict can be reconciled by the fact that primary hepatocytes have a high capacity for fatty acid oxidation, triglyceride synthesis and very low density lipoprotein secretion (7). We speculate that these pathways prevent intracellular fatty acids from accumulating to levels that activate PPARalpha . Interestingly, 20:5 (n-3) was the only PUFA tested here that activated PPARalpha . 20:5 (n-3) is reported to be poorly oxidized in mitochondria and poorly incorporated into complex lipids, such as triglycerides (7). Thus, 20:5 (n-3) might accumulate in the cell and mimic a state of fatty acid overload in the liver. Fatty acid overload resulting from high fat feeding (>50% calories as fat), uncompensated diabetes and liver disease have all been reported to increase peroxisomal beta -oxidation (26, 50, 51). Alternatively, 20:5 (n-3) might be metabolized to an active ligand. Recent studies have suggested that the leukotriene, LTB4, is a ligand for PPARalpha (52). Indeed, LTB4 is derived from 20:4 (n-6) by the action of 5-lipoxygenase and LTA4 hydrolase. If this pathway were operative, we would expect 20:4 (n-6) treatment of hepatocytes to activate PPARalpha and induce mRNAAOX. The lack of a 20:4 (n-6) effect on mRNAAOX and PPARalpha along with the low LTA4 hydrolase activity associated with liver cells (53) suggest that LTB4 is not the operative ligand for 20:5 (n-3) activation of PPARalpha . However, the in vitro model used in this work may lack factors present in the in vivo system.

In summary, PUFA induce peroxisomal and microsomal fatty acid oxidation and suppress de novo lipogenesis (2-15). This apparent coordinate regulation of lipid metabolism does not involve PPARalpha as a common mediator. While highly unsaturated n-3 fatty acids, such as 20:5, can activate PPARalpha resulting in increased mRNAAOX and mRNACYP4A2, PPARalpha does not mediate the suppressive effects of 18:2, 18:3 (n-3 and n-6), 20:4 (n-6), or 20:5 (n-3) on lipogenic gene expression. Thus, PUFA suppression of S14 and FAS gene transcription is mediated by a pathway that is independent of PPARalpha . The underlying mechanism of this alternative pathway is currently under investigation.


FOOTNOTES

*   The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
   To whom all correspondence should be addressed. Tel.: 517-355-6475 (ext. 1246); Fax: 517-355-5125; E-mail: Jump{at}pilot.msu.edu.
1   The abbreviations used are: PUFA, polyunsaturated fatty acids; PPAR, peroxisome proliferator-activated receptor; AOX, acyl-CoA oxidase; RXR, retinoid X receptor; FAS, fatty acid synthase; CYP4A2, cytochrome P450 4A2; PPRE, peroxisome proliferator response element; TK, thymidine kinase; CAT, chloramphenicol acetyltransferase; PCR, polymerase chain reaction.
2   B. Ren, A. Thelen, and D. B. Jump, unpublished results.
3   D. B. Jump, A. Thelen and M. Badin, manuscript in preparation.

ACKNOWLEDGEMENTS

We thank Michelle Mater, Karl Olson, and David Pan for critical review of the manuscript. We also thank Drs. T. Osumi, H. S. Sul, and L. Kedes for the cDNA probes used in these studies.


REFERENCES

  1. Clarke, S. D., and Jump, D. B. (1994) Annu. Rev. Nutr. 14, 83-98 [CrossRef][Medline] [Order article via Infotrieve]
  2. Neat, C. E., Thomassen, M. S., and Osmundsen, H. (1980) Biochem. J. 186, 369-371 [Medline] [Order article via Infotrieve]
  3. Thomassen, M. S., Christiansen, E. N., and Norum, K. R. (1982) Biochem. J. 206, 195-202 [Medline] [Order article via Infotrieve]
  4. Flatmark, T., Nilsson, A., Kvannes, J., Eikhom, T. S., Fukami, M. H., Kryvi, H., and Christiansen, E. N. (1988) Biochim. Biophys. Acta 962, 122-130 [Medline] [Order article via Infotrieve]
  5. Aarsland, A., Lundquist, M., Borretsen, B., and Berg, R. K. (1990) Lipids 25, 546-548 [CrossRef][Medline] [Order article via Infotrieve]
  6. Rambjor, G. S., Walen, S. L., Windsor, S. L., and Harris, W. S. (1996) Lipids 31, S45-49
  7. Rustan, A. C., Nossen, J. O., Christiansen, E. N., and Drevon, C. A. (1988) J. Lipids Res. 29, 1417-1426 [Abstract]
  8. Toussant, M. J., Wilson, M. D., and Clarke, S. D. (1981) J. Nutr. 111, 146-153
  9. Rustan, A. C., Christiansen, E. N., and Drevon, C. A. (1992) Biochem. J. 283, 333-339
  10. Willumsen, N., Hexeberg, S., Skorve, J., Lundquist, M., and Berge, R. K. (1993) J. Lipids Res. 34, 13-22 [Abstract]
  11. Nilsson, A., Prydz, K., Rortveit, T., and Christiansen, E. N. (1987) Biochim. Biophys. Acta 920, 114-119 [Medline] [Order article via Infotrieve]
  12. Valdes, E., Vega, P., Avalos, N., and Orellana, M. (1995) Lipids 30, 955-958 [Medline] [Order article via Infotrieve]
  13. Clarke, S. D., Armstrong, M. K., and Jump, D. B. (1990) J. Nutr. 120, 218-224
  14. Clarke, S. D., Armstrong, M. K., and Jump, D. B. (1990) J. Nutr. 120, 225-231
  15. Blake, W. L., and Clarke, S. D. (1990) J. Nutr. 120, 1727-1729
  16. Jump, D. B., Clarke, S. D., MacDougald, O. A., and Thelen, A. (1993) Proc. Natl. Acad. Aci. U. S. A. 90, 8454-8458 [Abstract/Free Full Text]
  17. Jump, D. B., Clarke, S. D., Thelen, A., and Liimatta, M. (1994) J. Lipid Res. 35, 1076-1084 [Abstract]
  18. Landschulz, K. T., Jump, D. B., MacDougald, O. A., and Lane, M. D. (1994) Biochem. Biophys. Res. Commun. 200, 763-768 [CrossRef][Medline] [Order article via Infotrieve]
  19. Ntambi, J. M. (1992) J. Biol. Chem. 267, 10925-10930 [Abstract/Free Full Text]
  20. Gottlicher, M., Widmark, E., Li, Q., and Gustafsson, J. A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 4653-4657 [Abstract/Free Full Text]
  21. Keller, H., Dreyer, C., Medin, J., Mahfoudi, A., Ozato, K., and Wahli, W. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 2160-2164 [Abstract/Free Full Text]
  22. Schoonjans, K., Steals, B., and Auwerx, J. (1996) J. Lipid Res. 37, 907-925 [Abstract]
  23. Kliewer, S. A., Forman, B. M., Blumberg, B., Ong, E. S., Borgmeyer, U., Mangelsdorf, D. J., Umesono, K., and Evans, R. M. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 7355-7359 [Abstract/Free Full Text]
  24. Braissant, O., Foufelle, F., Scotto, C., Dauca, M., and Wahli, W. (1996) Endocrinology 137, 354-366 [Abstract]
  25. Lalwani, N. D., Reddy, M. K., Qureshi, S. A., Sirtori, C. R., Abiko, Y., and Reddy, J. K. (1983) Hum. Toxicol. 2, 27-48 [Medline] [Order article via Infotrieve]
  26. Reddy, J. K., and Mannaerts, G. P. (1994) Annu. Rev. Nutr. 14, 343-370 [CrossRef][Medline] [Order article via Infotrieve]
  27. Issemann, I., and Green, S. (1990) Nature 347, 645-650 [CrossRef][Medline] [Order article via Infotrieve]
  28. Green, S., and Wahli, W. (1994) Mol. Cell. Endocrinol. 100, 149-153 [CrossRef][Medline] [Order article via Infotrieve]
  29. Kliewer, S. A., Umesono, K., Noonan, D. J., Heyman, R. A., and Evans, R. M. (1992) Nature 358, 771-774 [CrossRef][Medline] [Order article via Infotrieve]
  30. Muerhoff, A. S., Griffin, K. J., and Johnson, E. F. (1992) J. Biol. Chem. 267, 19051-19053 [Abstract/Free Full Text]
  31. Gearing, K. L., Crickmore, A., and Gustafsson, J. A. (1994) Cell 79, 1147-1156 [CrossRef][Medline] [Order article via Infotrieve]
  32. Keller, H., Givel, F., Perroud, M., and Wahli, W. (1995) Mol. Endocrinol. 9, 794-804 [Abstract]
  33. Isseman, I., Prince, R. A., Tugwood, J. D., and Green, S. (1993) J. Mol. Endocrinol. 11, 37-47 [Abstract]
  34. Hertz, R., Bishara-Shieban, J., and Bar-Tana, J. (1995) J. Biol. Chem. 270, 13470-13475 [Abstract/Free Full Text]
  35. Hertz, R., Seckbach, M., Zakin, M. M., and Bar-Tana, J. (1996) J. Biol. Chem. 271, 218-224 [Abstract/Free Full Text]
  36. Juge-Aubry, C. E., Gorla-Bajszczak, A., Pernin, A., Lemberger, T., Wahli, W., Burger, A. G., and Meier, C. A. (1995) J. Biol. Chem. 270, 18117-18122 [Abstract/Free Full Text]
  37. Chu, R., Madison, L. D., Lin, Y., Kopp, P., Rao, M. S., Jameison, J. L., and Reddy, J. K. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 11593-11597 [Abstract/Free Full Text]
  38. Ren, B., Thelen, A., and Jump, D. B. (1996) J. Biol. Chem. 271, 17167-17173 [Abstract/Free Full Text]
  39. Huang, Q., Alvares, K., Chu, R., Bradfield, C. A., and Reddy, J. K. (1994) J. Biol. Chem. 269, 8493-8497 [Abstract/Free Full Text]
  40. Lee, S. S. T., Pineau, T., Drago, J., Lee, E. J., Owens, J. W., Kroetz, K. L., Fernandez-Salguero, P. M., Westphal, H., and Gonzalez, F. J. (1995) Mol. Cell. Biol. 15, 3012-3022 [Abstract]
  41. Miyazawa, S., Osumi, T., Hashimoto, T., Ohno, K., Miura, S., and Fujiki, Y. (1989) Mol. Cell. Biol. 9, 83-91 [Abstract/Free Full Text]
  42. Paulauskis, J. D., and Sul, H. S. (1988) J. Biol. Chem. 263, 7049-7054 [Abstract/Free Full Text]
  43. Liang, P., and Pardee, A. (1992) Science 257, 967-970 [Abstract/Free Full Text]
  44. Sanger, F., Nicklen, S, and Coulson, A. R. (1977) Proc. Natl. Acad. Sci. U. S. A. 74, 5463-5467 [Abstract/Free Full Text]
  45. Jump, D. B., Ren, B, Clarke, S, and Thelen, A. (1995) Prostaglandins Leukot. Essent. Fatty Acids 52, 107-111 [CrossRef][Medline] [Order article via Infotrieve]
  46. Miller, C. W., and Ntambi, J. M. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 9443-9448 [Abstract/Free Full Text]
  47. Forman, B. M., Chen, J., and Evans, R. M. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 4312-4317 [Abstract/Free Full Text]
  48. Kliewer, S. A., Sundseth, S. S., Jones, S. A., Brown, P. J., Wisely, G. B., Koble, C. S., Devchand, P., Wahli, W., Willson, T. M., Lenhard, J. M., and Lehmann, J. M. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 4318-4323 [Abstract/Free Full Text]
  49. Krey, G., Braissant, O, L'Horset, F, Kalkhoven, E, Perroud, M, Parker, M. G., and Wahli, W. (1997) Mol. Endocrinol. 11, 779-791 [Abstract/Free Full Text]
  50. Kaikaus, R. M., Chan, W. K., Lysenko, N., Ray, R., Ortiz de Montellano, P. R., and Bass, N. M. (1993) J. Biol. Chem. 268, 9593-9603 [Abstract/Free Full Text]
  51. Kaikaus, R. M., Sui, Z., Lysenko, N., Wu, N. Y., Ortiz de Montellano, P. R., Ockner, R. K., and Bass, N. M. (1993) J. Biol. Chem. 268, 26866-26871 [Abstract/Free Full Text]
  52. Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J., and Wahli, W. (1996) Nature 384, 39-43 [CrossRef][Medline] [Order article via Infotrieve]
  53. Yokomizo, T., Uozumi, N., Takahashi, T., Kume, K., Izumi, T., and Shimizu, T. (1995) J. Lipid Mediat. Cell Signal. 12, 321-332 [CrossRef][Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Lipid Res.Home page
Y. Wang, M. Torres-Gonzalez, S. Tripathy, D. Botolin, B. Christian, and D. B. Jump
Elevated hepatic fatty acid elongase-5 activity affects multiple pathways controlling hepatic lipid and carbohydrate composition
J. Lipid Res., July 1, 2008; 49(7): 1538 - 1552.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
U. J. Jung, C. Torrejon, A. P Tighe, and R. J Deckelbaum
n-3 Fatty acids and cardiovascular disease: mechanisms underlying beneficial effects
Am. J. Clinical Nutrition, June 1, 2008; 87(6): 2003S - 2009S.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
S.-C. Hsu and C.-j. Huang
Reduced Fat Mass in Rats Fed a High Oleic Acid-Rich Safflower Oil Diet Is Associated with Changes in Expression of Hepatic PPAR{alpha} and Adipose SREBP-1c-Regulated Genes
J. Nutr., July 1, 2006; 136(7): 1779 - 1785.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
T. Hashimoto, N. Shimizu, T. Kimura, Y. Takahashi, and T. Ide
Polyunsaturated Fats Attenuate the Dietary Phytol-Induced Increase in Hepatic Fatty Acid Oxidation in Mice
J. Nutr., April 1, 2006; 136(4): 882 - 886.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
D. Patsouris, J. K. Reddy, M. Muller, and S. Kersten
Peroxisome Proliferator-Activated Receptor {alpha} Mediates the Effects of High-Fat Diet on Hepatic Gene Expression
Endocrinology, March 1, 2006; 147(3): 1508 - 1516.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
D. Botolin, Y. Wang, B. Christian, and D. B. Jump
Docosahexaneoic acid (22:6,n-3) regulates rat hepatocyte SREBP-1 nuclear abundance by Erk- and 26S proteasome-dependent pathways
J. Lipid Res., January 1, 2006; 47(1): 181 - 192.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
D. B. Jump, D. Botolin, Y. Wang, J. Xu, B. Christian, and O. Demeure
Fatty Acid Regulation of Hepatic Gene Transcription
J. Nutr., November 1, 2005; 135(11): 2503 - 2506.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
C. Le May, M. Cauzac, C. Diradourian, D. Perdereau, J. Girard, A.-F. Burnol, and J.-P. Pegorier
Fatty Acids Induce L-CPT I Gene Expression through a PPAR{alpha}-Independent Mechanism in Rat Hepatoma Cells
J. Nutr., October 1, 2005; 135(10): 2313 - 2319.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M. Hughes-Fulford, R. R. Tjandrawinata, C.-F. Li, and S. Sayyah
Arachidonic acid, an omega-6 fatty acid, induces cytoplasmic phospholipase A2 in prostate carcinoma cells
Carcinogenesis, September 1, 2005; 26(9): 1520 - 1526.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
N. Saravanan, A. Haseeb, N. Z Ehtesham, and Ghafoorunissa
Differential effects of dietary saturated and trans-fatty acids on expression of genes associated with insulin sensitivity in rat adipose tissue
Eur. J. Endocrinol., July 1, 2005; 153(1): 159 - 165.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
Y. Wang, D. Botolin, B. Christian, J. Busik, J. Xu, and D. B. Jump
Tissue-specific, nutritional, and developmental regulation of rat fatty acid elongases
J. Lipid Res., April 1, 2005; 46(4): 706 - 715.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
T. Ide
Interaction of Fish Oil and Conjugated Linoleic Acid in Affecting Hepatic Activity of Lipogenic Enzymes and Gene Expression in Liver and Adipose Tissue
Diabetes, February 1, 2005; 54(2): 412 - 423.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
X. Deng, M. B. Elam, H. G. Wilcox, L. M. Cagen, E. A. Park, R. Raghow, D. Patel, P. Kumar, A. Sheybani, and J. C. Russell
Dietary Olive Oil and Menhaden Oil Mitigate Induction of Lipogenesis in Hyperinsulinemic Corpulent JCR:LA-cp Rats: Microarray Analysis of Lipid-Related Gene Expression
Endocrinology, December 1, 2004; 145(12): 5847 - 5861.
[Abstract] [Full Text] [PDF]